Type II collagen markers in osteoarthritis: What do they indicate?

Current Opinion in Rheumatology

Volumn 19, Issue 5, 2007, Pages 444-450

  Henrotin, Yves ^a   Addison, Shelby ^b   Kraus, Virginia ^b   Deberg, Michelle ^a  

^a UNIVERSITY OF LIÈGE   (Belgium)

^b DUKE UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

Biomarkers; Cartilage; Osteoarthritis

Indexed keywords

COLLAGEN TYPE 2;

ARTHROPATHY; CARTILAGE; COLLAGEN DEGRADATION; DISEASE COURSE; DISEASE SEVERITY; HUMAN; INDIVIDUALIZATION; JOINT INJURY; MENISCECTOMY; NONHUMAN; OSTEOARTHRITIS; PHYSICAL ACTIVITY; PREDICTION; PRIORITY JOURNAL; REVIEW;

ANIMALS; BIOLOGICAL MARKERS; CARTILAGE; COLLAGEN TYPE II; DISEASE MODELS, ANIMAL; HUMANS; OSTEOARTHRITIS;

EID: 34548329878     PISSN: 10408711     EISSN: None     Source Type: Journal    
DOI: 10.1097/BOR.0b013e32829fb3b5     Document Type: Review

References (69)

1. Billinghurst RC, Dahlberg L, Ionescu M, et al. Enhanced cleavage of type II collagen by collagenases in osteoarthritic articular cartilage. J Clin Invest 1997; 99:1534-1545.
2. Otterness IG, Downs JT, Lane C, et al. Detection of collagenase-induced damage of collagen by 9A4, a monoclonal C-terminal neoepitope antibody. Matrix Biol 1999; 18:331-341.
3. Hollander AP, Heathfield TF, Webber C, et al. Increased damage to type II collagen in osteoarthritic articular cartilage detected by a new immunoassay. J Clin Invest 1994; 93:1722-1732.
4. Deberg M, Labasse A, Christgau S, et al. New serum biochemical markers (Coll 2-1 and Coll 2-1 NO2) for studying oxidative-related type II collagen network degradation in patients with osteoarthritis and rheumatoid arthritis. Osteoarthritis Cartilage 2005; 13:258-265.
5. Charni N, Juillet F, Garnero P. Urinary type II collagen helical peptide (HELIX-II) as a new biochemical marker of cartilage degradation in patients with osteoarthritis and rheumatoid arthritis. Arthritis Rheum 2005; 52:1081-1090.
6. Croucher LJ, Hollander AP. Differential detection of type II collagen N-terminal and C-terminal denaturation epitopes in degrading cartilage. Mol Pathol 1999; 52:323-331.
7. Moskowitz R, Atley L, Eyre D. Type II collagen C-telopeptide 2B4 epitope is a marker for cartilage degradation in familial arthritis [abstract]. Arthritis Rheum 1998; 41:S352.
8. Christgau S, Garnero P, Fledelius C, et al. Collagen type II C-telopeptide fragments as an index of cartilage degradation. Bone 2001; 29:209-215.
9. Sugiyama S, Itokazu M, Suzuki Y, Shimizu K. Procollagen II C propeptide level in the synovial fluid as a predictor of radiographic progression in early knee osteoarthritis. Ann Rheum Dis 2003; 62:27-32.
10. Oganesian A, Zhu Y, Sandell LJ. Type IIA procollagen amino propeptide is localized in human embryonic tissues. J Histochem Cytochem 1997; 45:1469-1480.
11. Zhu Y, Oganesian A, Keene DR, Sandell LJ. Type IIA procollagen containing the cysteine-rich amino propeptide is deposited in the extracellular matrix of prechondrogenic tissue and binds to TGF-beta1 and BMP-2. J Cell Biol 1999; 144:1069-1080.
12. Rousseau JC, Sandell LJ, Delmas PD, Garnero P. Development and clinical application in arthritis of a new immunoassay for serum type IIA procollagen NH2 propeptide. Methods Mol Med 2004; 101:25-37.
13. Bauer DC, Hunter DJ, Abramson SB, et al. Classification of osteoarthritis biomarkers: a proposed approach. Osteoarthritis Cartilage 2006; 14:723-727. This paper describes the criteria of the first classification system proposed by the Osteoarthritis Biomarkers network, a consortium of five US National Institutes of Health designated sites.
14. Downs JT, Lane CL, Nestor NB, et al. Analysis of collagenase-cleavage of type II collagen using a neoepitope ELISA. J Immunol Methods 2001; 247:25-34.
15. Poole AR, Ionescu M, Fitzcharles MA, Billinghurst RC. The assessment of cartilage degradation in vivo: development of an immunoassay for the measurement in body fluids of type II collagen cleaved by collagenases. J Immunol methods 2004; 294:145-153.
16. Oestergaard S, Chouinard L, Doyle N, et al. The utility of measuring C-terminal telopeptides of collagen type II (CTX-II) in serum and synovial fluid samples for estimation of articular cartilage status in experimental models of destructive joint diseases. Osteoarthritis Cartilage 2006; 14:670-679.
17. Deberg M, Dubuc JE, Labasse A, et al. One year follow-up of Coll2-1, Coll2-1NO2 and myeloperoxidase serum levels in OA patients after hip or knee replacement. Ann Rheum Dis 2007 (in press).
18. King KB, Lindsey CT, Dunn TC, et al. A study of the relationship between molecular biomarkers of joint degeneration and the magnetic resonance-measured characteristics of cartilage in 16 symptomatic knees. Magn Reson Imaging 2004; 22:1117-1123.
19. Hellio Le Graverand MP, Brandt KD, Mazzuca SA, et al. Association between concentrations of urinary type II collagen neoepitope (uTIINE) and joint space narrowing in patients with knee osteoarthritis. Osteoarthritis Cartilage 2006; 14:1189-1195.
20. Deberg MA, Labasse AH, Collette J, et al. One-year increase of Coll 2-1, a new marker of type II collagen degradation, in urine is highly predictive of radiological OA progression. Osteoarthritis Cartilage 2005; 13:1059-1065.
21. Cerejo R, Poole AR, Ionescu M, et al. The association between cartilage activity measuerd in serum and progression of knee osteoarthritis in patients with and without evidence of generalized disease [abstract]. Arthritis Rheum 2002; 46:S144.
22. Sharma L, Dunlop D, Ionescu M, et al. The ratio of collagen breakdown to collagen synthesis and its relationship with the progression of knee osteoarthritis [abstract]. Arthritis Rheum 2004; 50:S282. (642).
23. Cahue S, Sharma L, Dunlop D, et al. The ratio of type II collagen breakdown to synthesis and its relationship with the progression of knee osteoarthritis. Osteoarthritis Cartilage 2007 [Epub ahead of print]. This paper underlines the relevance of the degradation/synthesis marker ratios to predict the progression of osteoarthritis.
24. Bingham CO 3rd, Buckland-Wright JC, Garnero P, et al. Risedronate decreases biochemical markers of cartilage degradation but does not decrease symptoms or slow radiographic progression in patients with medial compartment osteoarthritis of the knee: results of the two-year multinational knee osteoarthritis structural arthritis study. Arthritis Rheum 2006; 54:3494-3507.
25. Alexandersen P, Karsdal MA, Qvist P, et al. Strontium ranelate reduces the urinary level of cartilage degradation biomarker CTX-II in postmenopausal women. Bone 2007; 40:218-222.
26. Bagger YZ, Tanko LB, Alexandersen P, et al. Oral salmon calcitonin induced suppression of urinary collagen type II degradation in postmenopausal women: a new potential treatment of osteoarthritis. Bone 2005; 37:425-430.
27. Manicourt DH, Devogelaer JP, Azria M, Silverman S. Rationale for the potential use of calcitonin in osteoarthritis. J Musculoskelet Neuronal Interact 2005; 5:285-293.
28. Gineyts E, Mo JA, Ko A, et al. Effects of ibuprofen on molecular markers of cartilage and synovium turnover in patients with knee osteoarthritis. Ann Rheum Dis 2004; 63:857-861.
29. Manicourt DH, Bevilacqua M, Righini V, et al. Comparative effect of nimesulide and ibuprofen on the urinary levels of collagen type II C-telopeptide degradation products and on the serum levels of hyaluronan and matrix metalloproteinases-3 and -13 in patients with flare-up of osteoarthritis. Drugs R D 2005; 6:261-271.
30. Henrotin Y, Deberg M, Dubuc JE, et al. Type II collagen peptides for measuring cartilage degradation. Biorheology 2004; 41:543-547.
31. Birmingham D, Vilim V, Kraus VB. Collagen biomarkers for arthritis applications. Biomarker Insights 2006; 2:61-67. This paper proposes a classification of the type II collagen biomarkers according the criteria of the BIPED classification of the Osteoarthritis Biomarkers Network.
32. Ishikawa T, Nishigaki F, Christgau S, et al. Cartilage destruction in collagen induced arthritis assessed with a new biochemical marker for collagen type II C-telopeptide fragments. J Rheumatol 2004; 31:1174-1179.
33. Sondergaard BC, Henriksen K, Wulf H, et al. Relative contribution of matrix metalloprotease and cysteine protease activities to cytokine-stimulated articular cartilage degradation. Osteoarthritis Cartilage 2006; 14:738-748.
34. Olsen AK, Sondergaard BC, Byrjalsen I, et al. Anabolic and catabolic function of chondrocyte ex vivo is reflected by the metabolic processing of type II collagen. Osteoarthritis Cartilage 2007; 15:335-342.
35. Song X, Zeng L, Jin W, et al. Secretory leukocyte protease inhibitor suppresses the inflammation and joint damage of bacterial cell wall-induced arthritis. J Exp Med 1999; 190:535-542.
36. Kojima T, Mwale F, Yasuda T, et al. Early degradation of type IX and type II collagen with the onset of experimental inflammatory arthritis. Arthritis Rheum 2001; 44:120-127.
37. Chu Q, Lopez M, Hayashi K, et al. Elevation of a collagenase generated type II collagen neoepitope and proteoglycan epitopes in synovial fluid following induction of joint instability in the dog. Osteoarthritis Cartilage 2002; 10:662-669.
38. El-Maadawy S, Wahl C, Pidoux I, et al. Induction of osteoarthritis of an active human MMP-13 transgene in cartilage. Arthritis Rheum 2003; 48:S432.(1077).
39. Celeste C, Ionescu M, Robin Poole A, Laverty S. Repeated intraarticular injections of triamcinolone acetonide alter cartilage matrix metabolism measured by biomarkers in synovial fluid. J Orthop Res 2005; 23:602-610.
40. Ameye L, Deberg M, Oliveira E, et al. Chemical biomarkers C2C, Coll2-1 and Coll2-1NO2 provide complementary information on type II collagen catabolism in healthy and osteoarthritic mice. Arthritis Rheum 2007 (in press).
41. Felice BR, Chichester CO, Barrach HJ. Type II collagen peptide release from rabbit articular cartilage. Ann N Y Acad Sci 1999; 878:590-593.
42. Nemirovskiy OV, Dufield DR, Sunyer T, et al. Discovery and development of a type II collagen neoepitope (TIINE) biomarker for matrix metalloproteinase activity: from in vitro to in vivo. Anal Biochem 2007; 361:93-101. This paper is a detailed characterization of a new type II collagen neoepitope (TIINE) generated by MMP-13.
43. Matyas JR, Atley L, Ionescu M, et al. Analysis of cartilage biomarkers in the early phases of canine experimental osteoarthritis. Arthritis Rheum 2004; 50:543-552.
44. Lindhorst E, Wachsmuth L, Kimmig N, et al. Increase in degraded collagen type II in synovial fluid early in the rabbit meniscectomy model of osteoarthritis. Osteoarthritis Cartilage 2005; 13:139-145.
45. De Ceuninck F, Sabatini M, Renoux V, et al. Urinary collagen type II C-telopeptide fragments are sensitive markers of matrix metalloproteinase- dependent cartilage degradation in rat adjuvant-induced arthritis. J Rheumatol 2003; 30:1561-1564.
46. Jordan KM, Syddall HE, Garnero P, et al. Urinary CTX-II and glucosylgalactosyl-pyridinoline are associated with the presence and severity of radiographic knee osteoarthritis in men. Ann Rheum Dis 2006; 65:871-877.
47. Mazieres B, Garnero P, Gueguen A, et al. Molecular markers of cartilage breakdown and synovitis at baseline as predictors of structural progression of hip osteoarthritis. The ECHODIAH Cohort. Ann Rheum Dis 2006; 65:354-359. This paper reports the first study including a large cohort in which the predictive value of 10 markers of radiologic hip progression were evaluated. This study demonstrated that combined measurements of urinary CTX-II and hyaluronan may be used as a predictor of structural progression of hip osteoarthritis.
48. Mazzuca SA, Brandt KD, Eyre DR, et al. Urinary levels of type II collagen C-telopeptide crosslink are unrelated to joint space narrowing in patients with knee osteoarthritis. Ann Rheum Dis 2006; 65:1055-1059.
49. Meulenbelt I, Kloppenburg M, Kroon HM, et al. Urinary CTX-II levels are associated with radiographic subtypes of osteoarthritis in hip, knee, hand, and facet joints in subject with familial osteoarthritis at multiple sites: the GARP study. Ann Rheum Dis 2006; 65:360-365.
50. Mouritzen U, Christgau S, Lehmann HJ, et al. Cartilage turnover assessed with a newly developed assay measuring collagen type II degradation products: influence of age, sex, menopause, hormone replacement therapy, and body mass index. Ann Rheum Dis 2003; 62:332-336.
51. Kong SY, Stabler TV, Criscione LG, et al. Diurnal variation of serum and urine biomarkers in patients with radiographic knee osteoarthritis. Arthritis Rheum 2006; 54:2496-2504. This study is the first study to investigate the diurnal variation in nine biomarkers in serum and two in urine. The majority of them are subject to diurnal variation and should be standardized in future osteoarthritis clinical trials.
52. Garnero P, Piperno M, Gineyts E, et al. Cross sectional evaluation of biochemical markers of bone, cartilage, and synovial tissue metabolism in patients with knee osteoarthritis: relations with disease activity and joint damage. Ann Rheum Dis 2001; 60:619-626.
53. Jung M, Christgau S, Lukoschek M, et al. Increased urinary concentration of collagen type II C-telopeptide fragments in patients with osteoarthritis. Pathobiology 2004; 71:70-76.
54. Reijman M, Hazes JM, Bierma-Zeinstra SM, et al. A new marker for osteoarthritis: cross-sectional and longitudinal approach. Arthritis Rheum 2004; 50:2471-2478.
55. Garnero P, Charni N, Juillet F, et al. Increased urinary type II collagen helical and C telopeptide levels are independently associated with a rapidly destructive hip osteoarthritis. Ann Rheum Dis 2006; 65:1639-1644.
56. Lohmander LS, Yoshihara Y, Roos H, et al. Procollagen II C-propeptide in joint fluid: changes in concentration with age, time after knee injury, and osteoarthritis. J Rheumatol 1996; 23:1765-1769.
57. Nelson F, Dahlberg L, Laverty S, et al. Evidence for altered synthesis of type II collagen in patients with osteoarthritis. J Clin Invest 1998; 102:2115-2125.
58. Rousseau JC, Zhu Y, Miossec P, et al. Serum levels of type IIA procollagen amino terminal propeptide (PIIANP) are decreased in patients with knee osteoarthritis and rheumatoid arthritis. Osteoarthritis Cartilage 2004; 12:440-447.
59. Garnero P, Sornay-Rendu E, Arlot M, et al. Association between spine disc degeneration and type II collagen degradation in postmenopausal women: the OFELY study. Arthritis Rheum 2004; 50:3137-3144.
60. Garnero P, Mazieres B, Gueguen A, et al. Cross-sectional association of 10 molecular markers of bone, cartilage, and synovium with disease activity and radiological joint damage in patients with hip osteoarthritis: the ECHODIAH cohort. J Rheumatol 2005; 32:697-703.
61. Garnero P. Use of biochemical markers to study and follow patients with osteoarthritis. Curr Rheumatol Rep 2006; 8:37-44.
62. Bruyere O, Genant H, Kothari M, et al. Longitudinal study of magnetic resonance imaging and standard X-rays to assess disease progression in osteoarthritis. Osteoarthritis Cartilage 2007; 15:98-103.
63. Garnero P. Biochemical markers in osteoarthritis: will they measure up? Nat Clin Pract 2006; 2:116-117.
64. Sharif M, Kirwan J, Charni N, et al. A 5-yr longitudinal study of type IIA collagen synthesis and total type II collagen degradation in patients with knee osteoarthritis: association with disease progression. Rheumatology (Oxford) 2007; 46:938-943. This report suggests that the combined measurement of markers of collagen synthesis and collagen degradation may be useful in identifying patients with knee osteoarthritis who are at increased risk for disease progression.
65. Garnero P, Ayral X, Rousseau JC, et al. Uncoupling of type II collagen synthesis and degradation predicts progression of joint damage in patients with knee osteoarthritis. Arthritis Rheum 2002; 46:2613-2624.
66. Bruyere O, Collette J, Kothari M, et al. Osteoarthritis, magnetic resonance imaging, and biochemical markers: a one year prospective study. Ann Rheum Dis 2006; 65:1050-1054. This study investigated for the first time the relation between biomarkers of bone, cartilage, and synovial remodeling and the structural progression of knee osteoarthritis, evaluated using magnetic resonance imaging.
67. Reginster JY, Deroisy R, Rovati LC, et al. Long-term effects of glucosamine sulphate on osteoarthritis progression: a randomised, placebo-controlled clinical trial. Lancet 2001; 357:251-256.
68. Christgau S, Henrotin Y, Tanko LB, et al. Osteoarthritic patients with high cartilage turnover show increased responsiveness to the cartilage protecting effects of glucosamine sulphate. Clin Exp Rheumatol 2004; 22:36-42.
69. Cibere J, Thorne A, Kopec JA, et al. Glucosamine sulfate and cartilage type II collagen degradation in patients with knee osteoarthritis: randomized discontinuation trial results employing biomarkers. J Rheumatol 2005; 32:896-902.